{"protocolSection": {"identificationModule": {"nctId": "NCT01405963", "orgStudyIdInfo": {"id": "20101183"}, "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma", "officialTitle": "Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma"}, "statusModule": {"statusVerifiedDate": "2022-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-10-31", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2013-04-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-07-21", "studyFirstSubmitQcDate": "2011-07-28", "studyFirstPostDateStruct": {"date": "2011-07-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-03-31", "resultsFirstSubmitQcDate": "2022-03-31", "resultsFirstPostDateStruct": {"date": "2022-10-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-03-31", "lastUpdatePostDateStruct": {"date": "2022-10-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the late and early asthmatic response after an allergen inhalation challenge in adults with mild atopic asthma after receiving multiple doses of tezepelumab (AMG 157), as well as the safety, tolerability, immunogenicity, and pharmacokinetics of multiple doses of tezepelumab in adults with mild atopic asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Amgen", "AMG 157", "Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 31, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo to tezepelumab administered by intravenous infusion on study days 1, 29, and 57.", "interventionNames": ["Drug: Placebo"]}, {"label": "Tezepelumab 700 mg", "type": "EXPERIMENTAL", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.", "interventionNames": ["Biological: Tezepelumab"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "Administered in a 1-hour intravenous infusion", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Tezepelumab", "description": "Administered in a 1-hour intravenous infusion", "armGroupLabels": ["Tezepelumab 700 mg"], "otherNames": ["AMG 157", "Tezspire"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction (measured by a fall in FEV1). FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR).\n\nThe percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during late (3-7 hour) asthmatic response time frame.", "timeFrame": "Days 42 and 84 at pre-allergen challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge"}, {"measure": "Time-Adjusted Area Under the Curve for the Percent Decrease From Pre-Allergen Challenge in Forced Expiratory Volume in 1 Second (FEV1) From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR).\n\nThe percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "timeFrame": "Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge"}], "secondaryOutcomes": [{"measure": "Number of Participants With Adverse Events", "description": "A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria:\n\n* fatal,\n* life-threatening,\n* requires in-patient hospitalization or prolongation of existing hospitalization,\n* results in persistent or significant disability/incapacity,\n* congenital anomaly/birth defect, and/or\n* other medically important serious event. The severity of each adverse event was graded by the Investigator as mild, moderate, severe, life-threatening, or fatal according to the Common Terminology Criteria for Adverse Events (Version 4).", "timeFrame": "Up to 169 days"}, {"measure": "Number of Participants With Grade \u2265 3 Laboratory Values", "description": "Laboratory toxicities were graded according to the Common Terminology Criteria for Adverse Events (Version 4) on a scale from grade 1 (mild) to 5 (death).", "timeFrame": "Up to 169 days"}, {"measure": "Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment", "description": "All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab.\n\nThe number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.", "timeFrame": "Days 29, 57, 85, 113, and 169"}, {"measure": "Maximum Percentage Decrease in FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during early (0-2 hour) asthmatic response time frame.", "timeFrame": "Days 42 and 84 at pre-allergen challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge"}, {"measure": "Time-Adjusted AUC for the Percent Decrease From Pre-Allergen Challenge in FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe percent change in FEV1 from pre-allergen challenge was calculated to each time point between 0 to 2 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "timeFrame": "Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge"}, {"measure": "Minimum FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe minimum FEV1 post onset of the allergen challenge for EAR is defined as the smallest value of FEV1 measured during 0 to 2 hours post allergen challenge.", "timeFrame": "Days 42 and 84 at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge"}, {"measure": "Time-Adjusted AUC for FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe area under the curve for the FEV1 between 0 to 2 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "timeFrame": "Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge"}, {"measure": "Minimum FEV1 From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR).\n\nThe minimum FEV1 post allergen challenge for LAR is defined as the smallest value of FEV1 measured during 3 to 7 hours post allergen challenge.", "timeFrame": "Days 42 and 84 at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge"}, {"measure": "Time-Adjusted AUC for FEV1 From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR).\n\nThe area under the curve for the FEV1 between 3 to 7 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "timeFrame": "Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge."}, {"measure": "Maximum Observed Serum Concentration (Cmax) of Tezepelumab", "description": "The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}, {"measure": "Time of Maximum Observed Concentration (Tmax) of Tezepelumab", "description": "The PK parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}, {"measure": "Minimum Observed Serum Concentration (Cmin) of Tezepelumab", "description": "The PK parameter Cmin was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}, {"measure": "Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab", "description": "The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.\n\nThe dosing interval (tau) was 28 days. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85."}, {"measure": "Accumulation Ratio Based on AUCtau", "description": "Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85."}, {"measure": "Accumulation Ratio Based on Cmax", "description": "Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose.", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}, {"measure": "Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab", "description": "The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}, {"measure": "Terminal Half-life (t1/2z) of Tezepelumab After Last Dose", "description": "The PK parameter t1/2,z was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "timeFrame": "Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female subjects with history of mild atopic asthma between 18 and 60 years-of-age\n* Body mass index (BMI) between 18 and 35 kg/m\\^2\n* Normal or clinically acceptable physical examination (PE), clinical laboratory values, and electrocardiogram (ECG); clinically acceptable PE includes history of mild atopic asthma\n* Used only inhaled short-acting \u03b22-agonists infrequently to treat asthma\n* No current exposure to allergens to which subject experiences asthmatic responses\n* No other lung disease, exacerbations of asthma or lower respiratory tract infections for at least 6 weeks prior to screening\n* Positive skin prick test to common aeroallergens at screening\n* Additional inclusion criteria apply\n\nExclusion Criteria:\n\n* History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;\n* History or current medical conditions that are contraindicated for methacholine challenge, such as myocardial infarction or stroke within previous 3 months, known cardiac disease, uncontrolled hypertension and aortic or cerebral aneurysm\n* Evidence of active or suspected bacterial, viral, fungal or parasitic infections within past 6 weeks\n* Subject has know type I/II diabetes\n* History of residential exposure to tuberculosis or has a positive purified protein derivative (PPD) or QuantiFERON test within 4 weeks before randomization\n* Subject who has history of malignancy of any type within 5 years prior to enrollment\n* Subjects tested positive for drugs/alcohol or nicotine use at screening\n* Subjects tested positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C\n* Additional exclusion criteria apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Sainte-Foy", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.75615, "lon": -71.29543}}, {"facility": "Research Site", "city": "Saskatoon", "state": "Saskatchewan", "zip": "S7N 0W8", "country": "Canada", "geoPoint": {"lat": 52.13238, "lon": -106.66892}}]}, "referencesModule": {"references": [{"pmid": "24846652", "type": "DERIVED", "citation": "Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C, Gorski KS, Smith L, Bautista E, Comeau MR, Leigh R, Parnes JR. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014 May 29;370(22):2102-10. doi: 10.1056/NEJMoa1402895. Epub 2014 May 20."}], "seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants were randomly assigned in a 1:1 ratio to receive tezepelumab or placebo.", "recruitmentDetails": "This proof-of-concept, randomized, double-blind, placebo-controlled study was conducted at 5 centers in Canada.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "FG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Moved Away", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Participants who received at least one dose of study drug.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "BG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.5", "spread": "11.2"}, {"groupId": "BG001", "value": "30.8", "spread": "10.9"}, {"groupId": "BG002", "value": "31.1", "spread": "10.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "27"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Forced Expiratory Volume in 1 Second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.335", "spread": "0.753"}, {"groupId": "BG001", "value": "3.358", "spread": "0.865"}, {"groupId": "BG002", "value": "3.346", "spread": "0.799"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Percentage Decrease in Forced Expiratory Volume in 1 Second (FEV1) at 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction (measured by a fall in FEV1). FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR).\n\nThe percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during late (3-7 hour) asthmatic response time frame.", "populationDescription": "Participants who received at least 1 dose of study drug with available data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Days 42 and 84 at pre-allergen challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-20.645", "spread": "11.554"}, {"groupId": "OG001", "value": "-16.949", "spread": "14.209"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.366", "spread": "14.686"}, {"groupId": "OG001", "value": "-12.064", "spread": "9.131"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 42 was evaluated using a repeated-measures analysis of covariance (ANCOVA) that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.09", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "7.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.30", "ciUpperLimit": "16.60", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.02", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "9.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.59", "ciUpperLimit": "18.23", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "PRIMARY", "title": "Time-Adjusted Area Under the Curve for the Percent Decrease From Pre-Allergen Challenge in Forced Expiratory Volume in 1 Second (FEV1) From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR).\n\nThe percent change in FEV1 from pre-challenge was calculated to each time point between 3 to 7 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "populationDescription": "Participants who received at least 1 dose of study drug and with available AUC data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.062", "spread": "8.231"}, {"groupId": "OG001", "value": "9.321", "spread": "10.787"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.864", "spread": "9.482"}, {"groupId": "OG001", "value": "7.569", "spread": "7.069"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 42 was evaluated using a repeated-measures analysis of covariance (ANCOVA) that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.11", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "-4.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.80", "ciUpperLimit": "1.10", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.07", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "-4.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.71", "ciUpperLimit": "0.39", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events", "description": "A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria:\n\n* fatal,\n* life-threatening,\n* requires in-patient hospitalization or prolongation of existing hospitalization,\n* results in persistent or significant disability/incapacity,\n* congenital anomaly/birth defect, and/or\n* other medically important serious event. The severity of each adverse event was graded by the Investigator as mild, moderate, severe, life-threatening, or fatal according to the Common Terminology Criteria for Adverse Events (Version 4).", "populationDescription": "Participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 169 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Any adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "Serious adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Leading to discontinuation from study", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Severe adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Life-threatening adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Fatal adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-related adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Grade \u2265 3 Laboratory Values", "description": "Laboratory toxicities were graded according to the Common Terminology Criteria for Adverse Events (Version 4) on a scale from grade 1 (mild) to 5 (death).", "populationDescription": "Participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 169 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Any Grade \u2265 3 Laboratory Toxicity", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Increased creatine kinase", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Decreased lymphocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment", "description": "All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab.\n\nThe number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.", "populationDescription": "Participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Days 29, 57, 85, 113, and 169", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"title": "Anti-tezepelumab binding antibodies", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Anti-tezepelumab neutralizing antibodies", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Percentage Decrease in FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe maximum percent decrease in FEV1 from pre-allergen challenge is the percent change in FEV1 representing the largest percentage decrease (or minimum percentage increase) from pre-allergen challenge FEV1 during early (0-2 hour) asthmatic response time frame.", "populationDescription": "Participants who received at least 1 dose of study drug with available data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Days 42 and 84 at pre-allergen challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.296", "spread": "10.084"}, {"groupId": "OG001", "value": "-22.501", "spread": "15.001"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.160", "spread": "15.280"}, {"groupId": "OG001", "value": "-20.990", "spread": "13.393"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "8.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.01", "ciUpperLimit": "17.13", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.06", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "10.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.46", "ciUpperLimit": "21.00", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Time-Adjusted AUC for the Percent Decrease From Pre-Allergen Challenge in FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe percent change in FEV1 from pre-allergen challenge was calculated to each time point between 0 to 2 hours post challenge. The area under the curve for the percent change at each time point was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "populationDescription": "Participants who received at least 1 dose of study drug and with available AUC data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.592", "spread": "8.432"}, {"groupId": "OG001", "value": "11.284", "spread": "11.509"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "20.179", "spread": "10.973"}, {"groupId": "OG001", "value": "11.297", "spread": "10.708"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.03", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "-6.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.56", "ciUpperLimit": "-0.60", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.03", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "-7.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.22", "ciUpperLimit": "-0.66", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Minimum FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe minimum FEV1 post onset of the allergen challenge for EAR is defined as the smallest value of FEV1 measured during 0 to 2 hours post allergen challenge.", "populationDescription": "Participants who received at least 1 dose of study drug with available data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Days 42 and 84 at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.211", "spread": "0.589"}, {"groupId": "OG001", "value": "2.682", "spread": "0.839"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.184", "spread": "0.720"}, {"groupId": "OG001", "value": "2.774", "spread": "0.826"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.05", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.68", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.08", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.84", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Time-Adjusted AUC for FEV1 From 0 to 2 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 0 to 2 hours post challenge to assess early asthmatic response (EAR).\n\nThe area under the curve for the FEV1 between 0 to 2 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "populationDescription": "Participants who received at least 1 dose of study drug and with available AUC data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Days 42 and 84 at pre-challenge and at 10, 20, 30, 45, 60, 90, and 120 minutes (0-2 hours) post challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.709", "spread": "0.695"}, {"groupId": "OG001", "value": "3.076", "spread": "0.844"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.607", "spread": "0.681"}, {"groupId": "OG001", "value": "3.120", "spread": "0.856"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.03", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.53", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in early asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.06", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.01", "ciUpperLimit": "0.66", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Minimum FEV1 From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post challenge to assess late asthmatic response (LAR).\n\nThe minimum FEV1 post allergen challenge for LAR is defined as the smallest value of FEV1 measured during 3 to 7 hours post allergen challenge.", "populationDescription": "Participants who received at least 1 dose of study drug with available data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Days 42 and 84 at 180, 240, 300, 360, and 420 minutes (3-7 hours) post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.659", "spread": "0.778"}, {"groupId": "OG001", "value": "2.943", "spread": "1.036"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.627", "spread": "0.864"}, {"groupId": "OG001", "value": "3.097", "spread": "0.827"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.01", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "0.70", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.01", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and Day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.11", "ciUpperLimit": "0.72", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Time-Adjusted AUC for FEV1 From 3 to 7 Hours Post Allergen Challenge", "description": "Participants underwent allergen inhalation challenge on study days 42 and 84 to induce airway bronchoconstriction. FEV1 was measured prior to the challenge and between 3 to 7 hours post allergen challenge to assess late asthmatic response (LAR).\n\nThe area under the curve for the FEV1 between 3 to 7 hours post allergen challenge was calculated using the linear trapezoidal rule, then time adjusted by dividing by the length of time over which the AUC was calculated.", "populationDescription": "Participants who received at least 1 dose of study drug and with available AUC data on each day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters", "timeFrame": "Days 42 and 84 at pre-challenge and at 180, 240, 300, 360, and 420 minutes (3-7 hours) post challenge.", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57."}, {"id": "OG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"title": "Day 42", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.940", "spread": "0.781"}, {"groupId": "OG001", "value": "3.188", "spread": "0.994"}]}]}, {"title": "Day 84", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.853", "spread": "0.780"}, {"groupId": "OG001", "value": "3.252", "spread": "0.831"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 42 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.02", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "0.45", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Treatment difference in late asthmatic response at day 84 was evaluated using a repeated-measures ANCOVA that included study treatment and study visit as independent variables, treatment by study visit as an interaction term, and the corresponding baseline value (as measured 14 days before the first dose of a study drug) as a model covariate.", "nonInferiorityType": "OTHER", "pValue": "0.15", "statisticalMethod": "ANCOVA", "statisticalComment": "Model includes treatment, visit, treatment by visit interaction as fixed effects and day -14 value as covariate.", "paramType": "Treatment Difference", "paramValue": "0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.44", "estimateComment": "Treatment difference estimate (tezepelumab minus placebo) is mean estimate based on ANCOVA."}]}, {"type": "SECONDARY", "title": "Maximum Observed Serum Concentration (Cmax) of Tezepelumab", "description": "The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The pharmacokinetic (PK) parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/mL", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "First dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "262", "spread": "73"}]}]}, {"title": "Last dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "325", "spread": "81"}]}]}]}, {"type": "SECONDARY", "title": "Time of Maximum Observed Concentration (Tmax) of Tezepelumab", "description": "The PK parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "First dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "lowerLimit": "1.0", "upperLimit": "5.2"}]}]}, {"title": "Last dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "lowerLimit": "1.1", "upperLimit": "5.0"}]}]}]}, {"type": "SECONDARY", "title": "Minimum Observed Serum Concentration (Cmin) of Tezepelumab", "description": "The PK parameter Cmin was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u03bcg/mL", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "First dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60.7", "spread": "20.8"}]}]}, {"title": "Last dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.7", "spread": "13.4"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab", "description": "The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods.\n\nThe dosing interval (tau) was 28 days. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day*\u03bcg/mL", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "classes": [{"title": "First dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2730", "spread": "700"}]}]}, {"title": "Last dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4420", "spread": "1250"}]}]}]}, {"type": "SECONDARY", "title": "Accumulation Ratio Based on AUCtau", "description": "Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, and 85.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.64", "spread": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "Accumulation Ratio Based on Cmax", "description": "Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after first dose and after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "First dose: Day 1 at predose and 1 and 4 hours postdose, and days 4, 8, 15, and 29 (predose); Last dose: Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.31", "spread": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) After Last Dose for Tezepelumab", "description": "The PK parameter AUCinf was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "day*\u03bcg/mL", "timeFrame": "Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8620", "spread": "2440"}]}]}]}, {"type": "SECONDARY", "title": "Terminal Half-life (t1/2z) of Tezepelumab After Last Dose", "description": "The PK parameter t1/2,z was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/mL.", "populationDescription": "The PK parameter analysis set includes participants for whom pharmacokinetic parameter estimates could be derived after last dose.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Day 57 predose, 1 and 4 hours postdose, and at days 60, 64, 71, 83, 84, 85, 113, and 169.", "groups": [{"id": "OG000", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.0", "spread": "4.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "169 days", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo administered by intravenous infusion on study days 1, 29, and 57.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 12, "otherNumAtRisk": 15}, {"id": "EG001", "title": "Tezepelumab 700 mg", "description": "Participants received 700 mg tezepelumab administered by intravenous infusion on study days 1, 29, and 57.", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 15, "otherNumAtRisk": 16}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Ear discomfort", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Eye pruritus", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Malaise", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Laryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 16}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Sensation of heaviness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 16}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Dyspnoea exertional", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 16}]}, {"term": "Painful respiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Pulmonary congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Sneezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Sputum discoloured", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Alopecia", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 16}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 16}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."}, "pointOfContact": {"title": "Study Director", "organization": "Amgen Inc.", "email": "medinfo@amgen.com", "phone": "866-572-6436"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}